CagriSema is a fixed-combination product name covering two separate molecules: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 analogue. CagriSema is sold here for laboratory research in 3 sizes (2.5mg + 2.5mg (5mg total) to 10mg + 10mg (20mg total)), from $75.00 a vial. It is not an FDA-approved medicine. Research use only, and never for people or animals.
CagriSema specifications
| Product name | CagriSema |
|---|---|
| Also sold as | cagrilintide semaglutide, cagrilintide and semaglutide blend |
| Physical form | Freeze-dried powder, a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 2.5mg + 2.5mg (5mg total) · 5mg + 5mg (10mg total) · 10mg + 10mg (20mg total) |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | Tested by Kovera Labs; each lot's certificate posts here when it is reported |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California by USPS with tracking on every order, same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is CagriSema, and what is it used for?
CagriSema is also listed and searched as cagrilintide semaglutide, cagrilintide and semaglutide blend. They all mean the same blend. A name is not a test, which is why the lot record further down counts for more than the wording on a label.
The vial holds Cagrilintide, Semaglutide freeze-dried together. Each component has its own formula and its own record; the certificate for this lot reports on the mixture as sold.
A fixed-combination product name covering two separate molecules: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 analogue.
Two distinct mechanisms in one product. Cagrilintide acts non-selectively at calcitonin family receptors — the amylin receptors and the calcitonin receptor. Semaglutide acts at the GLP-1 receptor. The combination rationale is that amylin and GLP-1 signalling act through different pathways and are proposed to be additive.
Investigational combination, developed by Novo Nordisk. The two components each have their own separate literature.
No approved product. Nothing here is a single molecule, and the properties of the combination are not the sum of the components.
CagriSema for sale: 2.5mg + 2.5mg (5mg total), 5mg + 5mg (10mg total) and 10mg + 10mg (20mg total) vials, price per mg
CagriSema is sold in 3 sizes here, 2.5mg + 2.5mg (5mg total), 5mg + 5mg (10mg total) and 10mg + 10mg (20mg total), from $75.00 a vial. CagriSema cost and CagriSema price per mg by size are in the table, at each volume tier and on subscription; the per-mg figure under each price is the one that compares across sizes.
Volume and subscription pricing by size
| Size | One vial | 10–19 vials−10% | 20 vials−15% | Subscribe monthly−6% from shipment 2 | Availability |
|---|---|---|---|---|---|
| CagriSema 2.5mg + 2.5mg (5mg total) | $75.00$15.00/mg | $67.50a vial · $13.50/mg | $63.75a vial · $12.75/mg | $70.50a vial, shipment 2 on · $14.10/mg | Backordered — waitlist |
| CagriSema 5mg + 5mg (10mg total) | $145.00$14.50/mg | $130.50a vial · $13.05/mg | $123.25a vial · $12.32/mg | $136.30a vial, shipment 2 on · $13.63/mg | Backordered — waitlist |
| CagriSema 10mg + 10mg (20mg total) | $150.00$7.50/mg | $135.00a vial · $6.75/mg | $127.50a vial · $6.38/mg | $141.00a vial, shipment 2 on · $7.05/mg | Backordered — waitlist |
Volume tiers are per size and do not combine across sizes (see bulk pricing). Subscribe & Save takes 6% every month, 4% every 2 months or 2% every 3 months off from shipment 2, two shipments minimum, and stacks on the volume tier: the lowest this record ever bills is $11.98 per mg, twenty 2.5mg + 2.5mg (5mg total) vials on a monthly subscription from shipment 2 onward.
Nothing is added at checkout except the USPS shipping you choose; dispatch and delivery are the same on every order. The cost-per-milligram tool ranks the whole catalog by price per mg.
Where to buy CagriSema: what to check before you order from anyone
Where to get CagriSema, and how to buy CagriSema online
CagriSema for sale, or CagriSema peptide for sale, means this page: one record, 3 sizes. You can buy CagriSema online here with guest checkout; verified in-stock orders placed before 12 PM Pacific are dispatched the same day.
Before ordering CagriSema from anyone, us included, run the 5 checks on verifying a certificate; the first is that the report resolves on the laboratory's own site, and a seller who cannot pass them is asking for the trust a certificate exists to replace.
Cagrilintide and Semaglutide: the blend, and each on its own
CagriSema is a blend name, not a molecule, written Cagrilintide and Semaglutide as often as CagriSema. What the vial holds is the components below, and each of them is documented on its own record with its own certificate. The name is not standardized between suppliers, so two vials called CagriSema from two sellers can hold different amounts, which is why the certificate matters more than the label.
| Record | Class | Formula | Avg. mass | Sizes here |
|---|---|---|---|---|
| CagriSema | A fixed-combination product name covering two separate molecules: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 analogue. | blend of 2 | — | 2.5mg + 2.5mg (5mg total) · 5mg + 5mg (10mg total) · 10mg + 10mg (20mg total) from $75.00 |
| Cagrilintide | Lipidated long-acting analogue of amylin (islet amyloid polypeptide). | C194H312N54O59S2 | 4409 | 2mg · 5mg · 10mg from $60.00 |
| Semaglutide | A peptide that works on the GLP-1 receptor. | C187H291N45O59 | 4114 | 5mg · 10mg · 15mg · 20mg · 30mg from $55.00 |
CagriSema guides and documentation
Written to answer the questions that come up around CagriSema specifically, what its paperwork should show, how it is handled, and how to judge a supplier selling it.
- CagriSema certificate of analysis: reading a two-peptide blend
- CagriSema Identity Testing: How It Is Confirmed
- CagriSema Storage and Stability in the Laboratory
The full library, grouped by what you came to answer, is in the laboratory guides.
The CagriSema certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run, how to read one covers what each field does and does not cover.
CagriSema certificates post here and in the certificate index when Kovera Labs reports on the lot.
Solution arithmetic for the bench, with no administration guidance: the vial concentration calculator, preset to CagriSema.
Where the FDA stands on CagriSema
FDA status, and what this listing is Not an FDA-approved drug product
The FDA has not approved this compound for anything, and nothing in this catalog is a medicine.
Status verified 2026-08-25. Check the primary source before relying on this summary.
It is sold as laboratory material under the research-use restriction below. Being listed is not an approval, and not a claim that it is safe, effective or right for any purpose.
CagriSema research: what the published studies examine
Status: No FDA-approved application. This compound is sold as laboratory material. Where research on it has been published, it sits at the animal, cell or early-human stage, and this record does not summarize what it found. A supplier is not a neutral judge of evidence about its own catalog.
CagriSema is not a molecule, it is two of them: cagrilintide and semaglutide co-formulated. Each acts on a different receptor system — cagrilintide across the calcitonin receptor family, semaglutide at the GLP-1 receptor — and the rationale for pairing them is that amylin signalling and GLP-1 signalling are separate pathways proposed to add rather than overlap. There is published evidence that targeting amylin receptors has the potential to act additively with GLP-1 receptor agonists, so the rationale is not invented.
But it remains a rationale: a pharmacological argument for why a combination should work is a hypothesis, and it is the kind of argument that reads like evidence without being any. Each component is documented on its own record, and for a research vial the more practical point is analytical: a two-component product requires a certificate that resolves each component separately by identity and quantity, which is a harder problem than a single-compound assay and one that some laboratories report only as a total.
| Reported observation | Model | Source |
|---|---|---|
| Reviewing the receptor pharmacology of AM833 (cagrilintide), the authors note increasing evidence that targeting the amylin receptors improves weight control and has the potential to act additively with other treatments such as GLP-1 receptor agonists — the stated basis for combining the two mechanisms. | recombinant receptor pharmacology across 25 endpoints | Fletcher and colleagues, AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists, Journal of Pharmacology and Experimental Therapeutics (2021)This supports the RATIONALE for combining. It is not a study of the combination. |
| The semaglutide component is a GLP-1 analogue differing from human GLP-1 at two positions with a fatty diacid at lysine 26, with reported GLP-1 receptor affinity of 0.38 nM and a plasma half-life of 46.1 hours in mini-pigs. It does not cross the blood-brain barrier, reaching central sites through the circumventricular organs. | receptor binding and mini-pig pharmacokinetics | Lau and colleagues, Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide, Journal of Medicinal Chemistry (2015) |
Open questions. The most useful thing to know is that no published receptor-level or preclinical study characterizes this pair as a combination — the evidence cited above is for each component separately, plus a stated expectation of additivity. Combination pharmacology is not the sum of its parts: two compounds sharing a vial can interact through shared clearance, altered stability in solution, or overlapping tolerability, and the gastrointestinal effects characteristic of both mechanisms are the obvious place for that to show. CagriSema is investigational and approved nowhere.
This page does not reproduce clinical efficacy endpoints. That is a deliberate and consistent choice across every incretin compound on this catalog: those results describe a supervised therapy given to patients under medical care, which is a different thing from laboratory material, and printing them beside a purchase control would blur that distinction rather than inform anyone. Tolerability findings from the same trials are reported, because how often a compound causes adverse events is a property of the compound.
Finally, the point that applies to every reseller including this one: a vial bearing one of these names is related to the developed molecule by claimed sequence identity alone, and that claim is exactly what an identity assay on the specific lot exists to test.
Each row above describes an observation in the stated model. None of it describes what CagriSema would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
How to store CagriSema: refrigeration and shelf life
Keep the sealed vial cold and out of the light and it stays as it left the lab. Once it is mixed into a solution, how long it holds up depends on the compound, what it was mixed with, how strong the solution is and how cold it is kept — too many variables for anyone to print one shelf life on a label. So laboratories write the date on whatever they prepare and keep their own record of it.
For solution preparation arithmetic on the bench, concentration, per-graduation values and molarity, use the vial concentration calculator, which opens with the CagriSema sizes stocked here already loaded. It covers laboratory measurement only and contains no administration guidance.
